CannabCo believes its PureCann™ technology has the potential to create a new odorless cannabis segment within the cannabis industry. 

As the legalization of cannabis continues to open up new markets, the global cannabis marketplace is projected to grow to reach US$73.6 billion by 2027, according to Grand View Research. The medical segment of the cannabis market grew the most in 2019, growing by 71 percent as cannabis was embraced as a legitimate medical product for treating conditions including cancer, arthritis, Parkinson’s disease, Alzheimer’s disease, chronic pain and inflammation.


The emergence of cannabis as both a recreational product and a critical component of a number of medicines has contributed to the increase in research and development conducted in the cannabis space. While cannabidiol and the emergence of CBD-based treatments have dominated the medical cannabis segment, the recreational cannabis space has begun to experience its own influx of improvements as legal cannabis begins to benefit from a legal and regulated marketplace.

PureCann™ and Odorless Cannabis

Canadian cannabis innovator Cannabco Pharmaceutical is commercializing a cannabis production technology, called PureCann™, that is designed to create a pure form of cannabis by eliminating the harshness and extracting the unnecessary components of the plant. The company’s goal is to create an odorless cannabis product that can be carried and consumed discretely. “There is no question that there exists a huge demand for odorless products beyond the standard combustion of dry bud,” said Mark Novak, COO of CannabCo. “We are currently exploring numerous products both consumable, and non-consumable which will be produced from the manufacturing facility using PureCann™ as the base technology.” PureCann™ is exclusive to Cannabco.

The following infographic, sponsored by CannabCo Pharmaceutical, is designed to educate investors regarding innovations in the cannabis cultivation industry including the company’s PureCann™ technology.

Odorless CannabisOdorless CannabisOdorless CannabisOdorless CannabisOdorless Cannabis

Click here to connect with CannabCo Pharmaceutical Corp and to request an investor presentation.

This infographic is sponsored by Cannabco Pharmaceutical. This infographic provides information which was sourced by the Investing News Network (INN) and approved by Cannabco Pharmaceutical, in order to help investors learn more about the company. Cannabco Pharmaceutical is a client of INN. The company’s campaign fees pay for INN to create and update this infographic.

This infographic was created according to INN editorial standards to educate investors.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Cannabco Pharmaceutical and seek advice from a qualified investment advisor.

Strong Innovation Pipeline Continues to Drive Market Share Growth
Broken Coast’s First Foray into Cannabis 2.0
Solei Introduces First Limited Release Vape on the Market
Solei, RIFF, Good Supply and B!NGO Expand Product Offerings

Aphria Inc. (” Aphria ” or the ” Company “) ( TSX: APHA and NASDAQ: APHA ), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, today announced the expansion of its 510 Vape offering across its award-winning adult-use brand portfolio.

Keep reading... Show less

Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court before the December 1 2020 DEADLINE . A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=aurora-cannabis-inc&id=2437 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email info@zhanginvestorlaw.com for information on the class action.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf Solutions“, “OILS”, or the “Company”), Canada’s most innovative cannabis extractor, is pleased to provide the following commercial and intellectual property update:

Cannabis Extraction Agreement with White Label Producer

Keep reading... Show less

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that it has closed today its previously announced “bought deal” short form prospectus offering of units (“ Unit s ”), including the exercise in full of the over-allotment option (the “ Offering ”).

Keep reading... Show less

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Executive Chairman, is scheduled to speak on a panel at the Cowen 2020 Boston Cannabis Conference on Wednesday, December 2, 2020 at 9:20 a.m. EST.

For more information regarding the Cowen 2020 Boston Cannabis Conference please visit: https://www.cowen.com/conferences-and-events/3rd-annual-boston-cannabis-conference/

Keep reading... Show less